Murphy Capital Management Inc. lowered its position in Johnson & Johnson (NYSE:JNJ) by 0.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 107,965 shares of the company’s stock after selling 610 shares during the period. Johnson & Johnson comprises approximately 2.0% of Murphy Capital Management Inc.’s portfolio, making the stock its 9th largest position. Murphy Capital Management Inc.’s holdings in Johnson & Johnson were worth $13,096,000 as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. Investec Asset Management LTD increased its stake in Johnson & Johnson by 49.2% in the first quarter. Investec Asset Management LTD now owns 5,050,411 shares of the company’s stock valued at $546,454,000 after buying an additional 1,665,644 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in Johnson & Johnson by 2.1% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 73,530,716 shares of the company’s stock valued at $7,956,023,000 after buying an additional 1,546,408 shares in the last quarter. TIAA CREF Investment Management LLC increased its stake in Johnson & Johnson by 12.5% in the first quarter. TIAA CREF Investment Management LLC now owns 13,848,797 shares of the company’s stock valued at $1,498,440,000 after buying an additional 1,534,277 shares in the last quarter. Virginia Retirement System acquired a new stake in Johnson & Johnson during the first quarter valued at $119,842,000. Finally, NN Investment Partners Holdings N.V. acquired a new stake in Johnson & Johnson during the first quarter valued at $92,331,000. 65.32% of the stock is owned by institutional investors.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) traded down 0.59% during midday trading on Friday, hitting $117.56. 5,640,519 shares of the stock were exchanged. The company has a market cap of $321.63 billion, a PE ratio of 21.91 and a beta of 0.62. Johnson & Johnson has a 12 month low of $94.28 and a 12 month high of $126.07. The firm’s 50 day moving average price is $118.72 and its 200 day moving average price is $117.37.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share for the quarter, topping the consensus estimate of $1.68 by $0.06. The company had revenue of $18.50 billion for the quarter, compared to the consensus estimate of $17.98 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. On average, equities research analysts forecast that Johnson & Johnson will post $6.69 earnings per share for the current fiscal year.

Several analysts have weighed in on JNJ shares. Barclays PLC reissued an “overweight” rating and issued a $125.00 price target (up from $120.00) on shares of Johnson & Johnson in a research note on Sunday, July 10th. Wells Fargo & Co. reissued a “buy” rating on shares of Johnson & Johnson in a research note on Monday, July 11th. Jefferies Group boosted their price target on shares of Johnson & Johnson from $109.00 to $113.00 and gave the stock a “hold” rating in a research note on Thursday, July 14th. Royal Bank Of Canada boosted their price target on shares of Johnson & Johnson from $125.00 to $133.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 20th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $132.00 price target on shares of Johnson & Johnson in a research note on Wednesday, July 20th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $120.20.

In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 2,935 shares of the business’s stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $125.01, for a total transaction of $366,904.35. Following the sale, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 41,146 shares of the business’s stock in a transaction that occurred on Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the sale, the vice president now directly owns 157,819 shares in the company, valued at approximately $19,728,953.19. The disclosure for this sale can be found here. Company insiders own 0.11% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.